In line with published literature, our analysis shows that the widespread adoption of TNF-alpha inhibitor biosimilars has been limited by the indication of these products to treat chronic conditions (e.g., rheumatoid arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis, etc.). This evidence concerns the gene TNF and ankylosing spondylitis.